59- Data Integrity, Informed Consent, and Recordkeeping in cGCP (S22E5)

Okay, so have you ever had one of those moments,
you know those times when like... you just absolutely
know you can't mess something up. Oh, yeah, totally.
Like the stakes are just so high. You know, if
one tiny thing goes wrong, it's like the whole
thing is going to just completely fall apart.
Yeah. So like developing a new medicine, for
instance. Right. People's lives depend on these
things. Oh, absolutely. And that's where risk
management and this idea of quality assurance.
Yeah. That's where it becomes so critical, especially
when we're talking about something like clinical
trials. And that's exactly what we're diving
into today. Yeah. So. If the thought of navigating
these complexities of clinical trials and how
to make sure they're run to the highest standards,
if that all seems a bit daunting. Yeah, can be.
This deep dive is here to help. Think of it like
we're giving you the cheat sheet, the spark notes
version of like how to understand data reliability
and, you know, Most importantly, the safety of
those participating in the trials. Yeah, and
we did a lot of research for this deep dive.
Oh, yeah. You know, we're talking the Code of
Federal Regulations, specifically parts 110,
111, 211, and 312. Got it. But we didn't stop
there. We also looked at ICH, the International
Council for Harmonization Guidelines. Right.
Global standards. Exactly. Global standards.
And of course, you can't do a deep dive without
checking out the expertise on YouTube. Right.
We looked at folks like EAS Consulting, Risk
Revolution. Yeah, those guys are great. And we
even looked at some insights from Devon Edwards.
Oh, yeah. Love his stuff. And of course, we read
through some very dense books on pharmaceutical
manufacturing and regulations. You're going to
love a good textbook. You know, they're a real
page turner. Yeah. Always a good time. So for
this deep dive, we really wanted to hone in on
risk management and quality assurance specifically
within clinical trials. Right. So we'll be breaking
down how compliance is maintained and what happens
when things, you know, inevitably kind of go
off script. Because it's gonna happen. Yeah,
it's gonna happen. So that's where deviation
management comes in. Right. And of course we'll
be looking at KPA and corrective and preventive
actions, you know, how the industry really learns
and grows from these experiences. Right, making
those mistakes but learning from them. Okay,
so first things first, let's talk about GMPs.
Good manufacturing practices. Good manufacturing
practices, the cornerstone of it all. For sure.
So how do they work to really ensure everything's
done right in a clinical trial and that the product
they're testing is, you know, actually good?
Well, at its heart, GMP, you know, it lays out
these ground rules for how to make high quality
medicine consistently and to make sure everything's
done by the book, you know, all the regulations.
So it's like the foundation. Yeah, the bedrock
of pharmaceutical quality. And there are these
five key elements, right? Exactly. Devon Edwards
really hit on people, premises, processes, products,
and procedures. And these aren't just, like,
nice suggestions. Right, no. They're like the
law and the ethics of the industry. It's the
real deal. It's the real deal. And I always find
it so interesting to think about, like, how did
we get here? It wasn't always so structured.
No. So what really drove the development of GMP?
Well, you know, Edwards pointed to the Pure Food
and Drug Act of 1906 as like a really important
early step. OK. Because back then, people were
worried about products that were unsafe or mislabeled.
Right. And so this act was kind of a response
to that. Right. But it was the sulfonylmide tragedy
in 1937. that really like underlined the need
for stronger regulations. Right. This was a heartbreaking
situation where a new liquid medicine used a
toxic solvent and there weren't any rules requiring
safety testing before it went to market. So sadly
it caused a lot of deaths and that event really
pushed for more comprehensive regulations that
we know now as GMPs. It's a really tragic example
but it highlights why these practices are in
place. Absolutely. It showed that trusting companies
to do the right thing wasn't enough. We needed
strong legally mandated practices to to keep
people safe. So GMPs are not just best practices.
They're the law. The law in following them is
not optional. It's a legal requirement for anyone
involved in making pharmaceuticals, including
the stuff used in clinical trials. Right. So
we understand why GMPs are so important. But
now let's talk about the... Where you know the
physical spaces and equipment used in developing
and manufacturing these products the premises
the premise exactly So how does that environment
actually play into quality and safety? It's a
huge factor You know the way these facilities
are designed and maintained is super important
for preventing contamination and that can directly
affect the quality of the product, and obviously
the safety of the people in the trial. I think
about something as basic as a floor drain. They
need to have these things called air breaks,
which stop sewage from backing up and potentially
contaminating the manufacturing area. That makes
sense. And Jacobs and Signore, they stress that
having good waste removal systems, easily accessible
places to wash up, and really clear written cleaning
procedures are all essential. for maintaining
a controlled environment. It's all about minimizing
those risks. Exactly. You don't want something
in the environment messing up the medicine being
developed. Right. And it's not just the building
itself, right? No. It's also the equipment used
in the process. Oh, yeah. The equipment is critical.
CFR 21 Part 110 actually requires proper ventilation
to control airborne contaminants and odors. And
you've got to have solid pest control measures
to prevent any contamination from pests. So everything's
about creating a space where the product is protected.
And speaking of protection, CFR 21 part 211 is
all about the equipment, mandating that it needs
to be designed, sized, and positioned so that
it can be thoroughly cleaned and maintained to
prevent any adulteration of the drug. If equipment's
hard to clean. It can become a breeding ground
for contaminants even if you have like the cleanest
facility in the world. It's true. I've heard
the term equipment qualification thrown around
quite a bit. DQ, IQ, OQ, PQ. Yeah, that whole
alphabet soup. What is that all about? So you
can think of it as like building this documented
confidence in the equipment at each stage of
its life. So as ES Consulting Group explained
design qualification or DQ, it's basically confirming
that the equipment is designed to meet the specific
requirements and regulations. So it's designed
right from the start. Exactly. And then Installation
Qualification IQ verifies that the equipment
is actually installed correctly. Following the
manufacturer's specifications. Exactly. By the
book. And they have operational qualification
OQ. OK. This demonstrates that the equipment
runs as intended across all the operating ranges.
the ones it's expected to encounter. So making
sure it actually does what it's supposed to do.
Right. And then finally you have performance
qualification PQ, which proves that the equipment
consistently produces the desired quality product
under normal production conditions. It's like
a step -by -step process to make sure the equipment
is suitable and it's working reliably. And it's
not just a one -time thing. Right. You have to
do re -qualification periodically, especially
after big changes or repairs or even if the equipment
is moved. Even moving it. Yeah, even moving something
like an HPLC system can mess with this performance,
as ES Consulting Group pointed out. And all of
these qualification steps all have to be documented
carefully in standard operating procedures, or
SOPs, and in these detailed qualification protocols.
It seems like quite a process. Oh, it is. What
about simpler equipment, though? Like a pH meter
in a lab, does that have to go through that whole
rigmarole? Actually, no EAS consulting group
clarified that while big complex systems go through
the full DQ, IQ, OQ, PQ, simpler instruments
just need to be calibrated before they're used
for the first time and then at regular intervals.
Makes sense. So for those big stationary systems,
calibration is often part of the PQ phase. But
for those portable instruments like the pH meters
or balances, calibration happens more frequently.
So it's really about making sure the instrument
is giving you reliable readings. Exactly. And
the key is really no matter what, whether it's
qualification or calibration, everything needs
to be written down. In those log books. Exactly.
Got to have detailed log books documenting all
those activities. So we've talked about the physical
environment, the tools. Now let's get into the
actual processes of developing and manufacturing
these drugs used in trials. So how do we ensure
quality and compliance during this phase? That's
where standard operating procedures or SOPs come
in. It is SOPs. They are absolutely critical.
EAS consulting group really stressed that SOPs
provide a detailed guide for every test and every
single manufacturing process, and the golden
rule here. If it's not written down, it didn't
happen. Exactly. If it's not documented in SOP
and followed, it's like it never happened from
a regulatory standpoint. You've got to have those
standardized procedures to make sure everything
is consistent and reproducible. Exactly. And
CFR 21, Part 111, it specifically mandates written
procedures for so many activities. Like what
kind of things? Oh, you know, cleaning and sanitizing
equipment and the facilities themselves, preventing
contamination, ensuring that materials are handled
in a sanitary way, and even preventing mix -ups
when you're packaging and labeling. It's all
labeled. Yes. And these aren't just suggestions.
They're legal requirements. Yeah. You know, designed
to protect the quality of the product and the
patient's safety. And it's not enough to just
write these procedures down, right? No. You've
got to prove that they actually work consistently.
Right. And that's where process validation enters
the picture. OK. I remember us talking about
that in a previous deep dive. So remind me, what
is it again? So process validation is about establishing
documented proof that a specific process carried
out under very specific conditions consistently
creates a product that meets those predetermined
quality specs. So it's showing that your process
reliably churns out a good product. Exactly.
And it's not just about having these written
procedures for production and process control.
You also have to keep really detailed documentation.
Write down everything. Yes, as it happens. Contemporaneous
documentation, they call it. That's so interesting.
It is. We talked about cleaning earlier with
the facilities. But it sounds like cleaning protocols
are a whole other beast on their own. Oh yeah,
they're essential. They're non -negotiable. You
know, as we discussed in season eight, and as
CFR 21 parts 110 and 111 highlight robust cleaning
protocols are key for preventing both contamination
and mix -ups between products. Makes sense. This
includes having very specific cleaning schedules
and validated cleaning procedures, you know,
making sure those cleaning methods actually work.
And it even goes into the design of the facility
itself, like using airlocks to minimize contamination.
So many layers of prevention. Exactly. Even with
all that in such a complex field like drug development,
things can still slip through the cracks. Right.
And that's where risk management comes in, I
think. Exactly. Quality risk management, or QRM,
it's a systematic way to identify, assess control,
and review potential risks to the quality of
a drug throughout its whole life cycle. So it's
not just putting out fires as they pop up. It's
about anticipating problems and putting controls
in place beforehand. Exactly. It's a proactive
approach instead of a reactive one. So what are
the key questions you ask when you're doing this
risk assessment? Well, Rodriguez -Prez really
laid it out for us. The first one is what could
go wrong. Second, how likely is that to actually
happen? And then if it did happen, how bad would
the consequences be? Makes sense. you know, by
systematically going through these questions,
you can then figure out what risks to focus on
and how to mitigate them. So it's all about prioritizing
your efforts. Exactly. Are there any specific
methods or tools that are used for risk assessment
in this field? Oh, yeah. Definitely one that's
often used is failure mode and effects analysis,
or FMEA, as Rodriguez Perez mentioned. OK. And
it's a very structured way to identify potential
failure points within a process. Yeah. To then
figure out how likely those failures are, how
severe they would be, and then what you can do
to reduce or eliminate those risks. So it's like
preemptive troubleshooting. Exactly. And risk
management. It's not just like a separate thing,
right? It's woven into all the other aspects
of GMP. Absolutely. As we discussed in a season
two, deep dive risk management principles are
a part of equipment qualification, change control
procedures, and all the other elements of GMP.
It's like the guiding principle for making informed
decisions at every single stage. And when we
talk about clinical trials specifically and the
responsibilities of investigators, how does this
concept of risk management play in? Well, the
FDA, they emphasize the importance of what they
call risk proportionality in clinical trial design
and oversight. They talk about this in their
CITC Day 3 training. And it's basically about
making sure your monitoring efforts and resources
are focused on the data points and processes
that are most critical for the study's integrity
and the participant's safety. So you're not just
looking at every single piece of data? No, it's
about strategically allocating your resources.
Based on the level of risk? Exactly. And it seems
like the whole approach to risk management is
evolving. Oh, for sure. I've been hearing more
about comprehensive contamination control strategies.
Right. And Risk Revolution, in their analysis
of the new Annex 1 guidelines, they highlighted
this growing expectation for manufacturers to
have a formal, documented, and implemented contamination
control strategy. So it's not just about hoping
contamination doesn't happen. No, it's about
being proactive and having a plan. So even with
all these precautions in place, there's still
gonna be times when things deviate from the validated
processes. Right, deviations happen. Then what?
Deviations from validated processes are a no
-go, and they have to be thoroughly addressed,
as both Jacobs and Signore and our season eight
deep dive pointed out. And this is where, you
know, deviation management and CAIA... corrective
and preventive actions. Yes, they really come
into play. You've mentioned K -Pay a few times,
so if something goes wrong or an issue is flagged,
K -Pay is that structured way to deal with it.
Exactly. K -Pay is a systematic process. It investigates
and addresses any deviations, non -conformances,
audit findings, and most importantly, it's about
preventing them from happening again. It's not
just about fixing the immediate problem. It's
about understanding the why. Exactly, the root
cause, and then taking steps to prevent it from
happening again. Our season six deep dive and
Rodriguez Perez both outlined this process really
well. So what are those key steps in the CAPIE
process? Well, the first and most important step
is to figure out the root cause. You know, do
a thorough root cause analysis. OK. You can't
really fix a problem if you're just treating
the symptoms you have to get to the heart of
the issue once you've identified the root cause,
then you can implement corrective actions to
address the immediate problem and bring everything
back into compliance. So get things back on track.
Exactly. But the real power of CUPPA is in those
preventive actions, the steps you take to stop
similar problems from happening again. And often
this involves addressing, like, weaknesses in
the system itself. This is a more long -term
solution. It's not just a band -aid. No, and
taking those corrective actions quicker, that's
crucial. And then you have to monitor to make
sure those actions are actually working, you
know, as we discussed in season six. Right. And
then Rodriguez Perez pointed out that if there
are any out of specification or OOS test results,
you have to broaden the investigation to include...
other batches or products that could be affected,
not just the one with the OOS result. And then
you have process trending, which is analyzing
data over time that helps you catch potential
quality issues before they become big problems.
So you're constantly looking for those early
warning signs. Exactly. And all of this generates
so much data and documentation. Right. So how
do you ensure that all that information is accurate
and reliable. That's where quality control and
good documentation practices come in. Absolutely.
And strong lab controls are key. As EAS Consulting
Group explained, this means having qualified
and regularly calibrated equipment, following
clearly defined test methods, which are detailed
in those SOPs, and documenting everything meticulously
and accurately. So those SOPs for test methods,
what kind of info is usually in those? A test
method SOP is a very detailed guide on how to
perform a specific lab test. In EAS Consulting
Group, Group noted that it needs to include every
single step of the procedure, whether the method
was developed in -house or adopted from an official
source like the USP. OK. It will usually have
sections on safety precautions for handling chemicals,
a full list of the reagents and materials needed,
clear instructions on how to prep standards and
media, and examples of the data you should expect,
like spectra or chromatograms. And it will even
have example calculations and guidelines for
reporting results. That's very thorough. Oh,
it is. And beyond those specific test methods,
there are other controls in place in the lab
too. Oh, like what? Well, labs use a variety
of systems to ensure data integrity and proper
sample handling. Things like using standardized
forms for submitting samples, a strict chain
of custody to track those samples from the time
they're collected to when they're analyzed, standardized
forms for preparing media and chemical reagents,
and then you have these data review checklists
that make sure every part of the analysis is
done and documented correctly. So many checks
and balances. Right. It's all about making sure
the data is reliable. And then, of course, there's
the documentation. I've heard about the LCOA
Plus principles. What are those all about? LCOA
Plus, it represents the fundamental principles
of good documentation practices, or GDP. GDP?
Yes. And Sila did a great job explaining this.
OK. So it's an acronym it stands for, attributable.
So it needs to be clear. Who did what? Okay.
Legible, meaning all entries have to be readable.
Contemporaneous, the record has to be made at
the time the activity happened. Original, meaning
it's the first record of the data. Yeah. Accurate,
meaning the information is correct and truthful.
Gotcha. And then the lie plus, add some other
important things. Complete, so all the relevant
data is included. Consistent, meaning the data
makes sense and is in the right order. enduring
meaning the records are kept for the required
time and available meaning you can easily find
those records. So it's like the who what when
where why and how of data. Exactly. It's all
about ensuring that the data is trustworthy and
for electronic systems it's also essential to
have audit trails that track any changes to the
data. So it's all about transparency. Exactly.
And if you make a mistake in your documentation
you can't just erase it right? Nope. You have
to draw a single line through the mistake initial
and date the correction and write a brief explanation
for the change. This makes sure there's a clear
record of what happened and who made the correction.
It's about accountability. Exactly. And this
applies to both paper and electronic records.
And for really important documents, you often
need a second person to review it. A peer review.
Yes, to double check that everything is accurate
and complete. So how long do you have to keep
all these records? Well, CFR 21 Part 211 says
that records for drug product badges have to
be kept for at least one year. after the batch's
expiration date. And for some over -the -counter
drugs that don't have an expiration date, it's
usually three years after the batch was distributed.
And with all these rules and regulations, there
must be some serious oversight to make sure everyone's
following them. Oh yeah, the FDA plays a huge
role in enforcing these regulations. And they
do that through inspections, which are often
conducted under their bioresearch monitoring
program, as CARA -LARO, from the FDA, explained,
during CITC Day 3. And the main goals of these
inspections are to protect people participating
in research, to verify the quality of the research
data, and to ensure everyone is following the
rules. And these inspections aren't just for
manufacturing facilities, right? No. They also
inspect the clinical trial sites where the research
is being conducted. So they're really checking
every step of the process. Exactly. The FDA does
good clinical practice or GCP inspections at
those trial sites. And the Office of Scientific
Investigations or OSI within the FDA, they're
really involved in the GCP review process, especially
for new drug applications and biologist license
applications. So what is GCP exactly? So GCP,
it's a set of ethical and scientific quality
standards that have to be followed when designing,
conducting, recording, and reporting clinical
trials that involve people. So it's all about
making sure the data is reliable and that people
in the trials are protected. Exactly. And so
during an FDA inspection, investigators will
go through things like the study protocols, the
informed consent forms. We'll check the qualifications
of the investigators and staff, they'll look
at the data and other records and really assess
how the clinical trial site is being run. It
sounds very Oh, it is. They're checking for compliance
with FDA regulations and GCP guidelines. And
if they find something? Right. If the investigators
see any potential violations or areas of concern,
they issue a Form 483, which lists those observations.
And then the firm that was inspected has to respond
in writing, usually within 15 business days,
outlining exactly what they're going to do to
fix those issues. And that's where KPE comes
in again. So what happens if ... a company or
research site just doesn't comply. Well, our
sources didn't get into specifics about enforcement
actions, but we know that the consequences can
be pretty serious. Right. They range from warning
letters for minor violations to more significant
actions like putting a hold on studies or even
withdrawing drug approvals if serious problems
are found and not fixed. It's really about making
sure people are protected. Exactly. And being
transparent with the regulatory agencies is also
key, right? Absolutely. Open communication is
essential for maintaining compliance. as we discussed
in season seven. So to sum it all up, making
sure new medicines are safe and effective is
a huge undertaking. It really is. With so much
oversight and attention to detail. Absolutely
and it all relies on this interconnected web
of good manufacturing practices. proactive risk
management, strong quality assurance systems,
and sticking to the regulations. And it's not
just about reacting to problems. It's about building
quality into every single step of the way. Exactly.
And being super meticulous with documentation
and really fostering that culture of quality
and safety throughout the entire process. It's
about protecting patients and ensuring that the
research is sound. Exactly. By taking these proactive
measures and really sweating the details. Right.
From how facilities are designed to how accurately
information is documented, the industry is constantly
working to minimize risks, ensure the data from
clinical trials is reliable, and most importantly,
protect the health and well -being of the people
in these trials. This has been a really insightful
deep dive. I think it really makes you appreciate
all the work that goes into bringing new medicines
to the people who need them. It's a huge team
effort. And it kind of makes you wonder... How
could we apply these same principles of risk
management and quality assurance to other areas
of our lives? Right. You know, outside of pharmaceuticals?
That's a great question to think about. Where
do you need to be extra careful and prevent mistakes?
Exactly. Could a more systematic approach help
you there? You know, to where you're identifying
potential risks, putting preventative measures
in place, and being really rigorous about quality.
Right. Could that lead to more dependable and
trustworthy outcomes in other parts of your life?
or your work. It's a thought -provoking idea.
It is. It shows that this isn't just concept
for pharmaceuticals. It's a way of thinking that
can be applied to so many complex situations.
Food for thought. Food for thought.